Resverlogix Corp RVX"-CA:Toronto Stock Exchange

*Data is delayed | CAD
Last | 06/09/21 EDT
0.01UNCH (UNCH)
52 week range
0.01 - 0.61

...

Loading . . .
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close0.01
  • 52 Week High0.61
  • 52 Week High Date09/28/20
  • 52 Week Low0.01
  • 52 Week Low Date06/09/21

Key Stats

  • Market Cap-
  • Shares Out-
  • 10 Day Average Volume-
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close0.01
  • 52 Week High0.61
  • 52 Week High Date09/28/20
  • 52 Week Low0.01
  • 52 Week Low Date06/09/21
  • Market Cap-
  • Shares Out-
  • 10 Day Average Volume-
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

RATIOS/PROFITABILITY

  • EPS (TTM)-
  • P/E (TTM)-
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-
  • ROE (MRQ)-
  • Revenue (MRQ)-
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Resverlogix Corp

There is no recent news for this security.

Latest From Our Partners

There is no recent news for this security.

Profile

MORE
Resverlogix Corp is Canada-based clinical-stage biotechnology company. The Company is developing apabetalone (RVX-208), a molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is the BET inhibitor selective for the second bromodomain (BD2) within the BET protein called BRD4. This selective inhibition of apabetalone on BD2 produces a specific set of...
Donald McCaffrey
Chairman
A. Brad Cann
Chief Financial Officer
Address
300-4820 Richard Rd SW
Calgary, AB
T3E 6L1
Canada